Alimera Sciences Announces 2022 Financial Results and Business Update
• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User…
• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User…
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate…
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate…
— Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led…
— Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led…
If subsequently approved, Entresto will be the first and only approved therapy for the treatment…
If subsequently approved, Entresto will be the first and only approved therapy for the treatment…
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the…
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the…
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance…
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance…
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, March 31, 2023 (GLOBE…
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, March 31, 2023 (GLOBE…
RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
Completed reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2022 with…
Completed reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2022 with…
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the…